Maximum Dose of Enoxaparin for Adults with ACS
For adults with acute coronary syndrome, the maximum dose of enoxaparin is 100 mg for the first two doses when used in patients under 75 years receiving fibrinolytic therapy, or 75 mg for the first two doses in patients 75 years or older receiving fibrinolytic therapy. 1
Dosing Framework by Clinical Scenario
The maximum dose varies based on the specific ACS treatment strategy:
Initial Medical Management (No Fibrinolysis)
- Standard dosing: 1 mg/kg subcutaneous every 12 hours 1
- No explicit maximum is stated for this indication in the guidelines
- However, research demonstrates that doses exceeding recommended weight-based dosing by >10 mg significantly increase major bleeding (OR 1.43) and mortality (OR 1.35) 2
With Fibrinolytic Therapy
This scenario has explicit maximum doses 1:
For patients <75 years:
- 30 mg IV bolus initially
- Then 1 mg/kg subcutaneous every 12 hours
- Maximum: 100 mg for the first 2 doses only
For patients ≥75 years:
- No IV bolus
- 0.75 mg/kg subcutaneous every 12 hours
- Maximum: 75 mg for the first 2 doses only
PCI Support Dosing
- For patients not previously anticoagulated: 0.5-0.75 mg/kg IV bolus 1
- For patients on prior enoxaparin: 0.3 mg IV if last dose was 8-12 hours prior 1
Critical Dose Adjustments
Renal Impairment (CrCl <30 mL/min)
Mandatory dose reduction regardless of indication 1:
- Reduce to 1 mg/kg subcutaneous every 24 hours (not every 12 hours)
- This applies to all ACS scenarios
- Enoxaparin clearance decreases by 44% in severe renal impairment, causing significant drug accumulation 3
Key Safety Considerations
High-risk populations for overdosing 2:
- Elderly patients (median age 78 years in overdosed group)
- Lower body weight patients (BMI 26.2 vs 27.8)
- Female patients (59.5% of overdosed patients)
The evidence is unequivocal: Nearly 19% of ACS patients receive excess doses in real-world practice, and this directly correlates with increased major bleeding and death 2. The most common error is failure to adjust for renal function and body weight.
Avoid the common pitfall of using fixed doses rather than weight-based dosing, particularly in elderly, small-framed, or renally impaired patients where even small absolute overdoses translate to significant relative overdosing.
Therapeutic Monitoring
While not routinely required, maintaining anti-Xa levels between 0.5-1.2 IU/mL is associated with optimal outcomes 4. Levels <0.5 IU/mL independently predict 3-fold higher 30-day mortality, while the standard weight-based dosing achieves therapeutic levels in 93% of patients 4.